Biocardia stock.

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%?Nov 7, 2023 · BCDA Stock Shows Promising Performance with Potential 863.86% Increase: Analysts Recommend Buying BioCardia Inc. BCDA stock has shown promising performance on November 7, 2023, according to data sourced from CNN Money. The median target price is $4.00, indicating a potential increase of 863.86% from the last recorded price of $0.42. Biocardia Inc stock price (BCDA) NASDAQ: BCDA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Biocardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Nov 24, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for BioCardia stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for BCDA. The average twelve-month price prediction for BioCardia is $4.00 with a high price target of $4.00 and a low price target of $4.00.

SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards …

Stock analysis for BioCardia Inc (BCDA:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

BioCardia BCDA is set to give its latest quarterly earnings report on Wednesday, 2023-11-08. ... Stock Performance. Shares of BioCardia were trading at $0.405 as of November 06.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire)-15.27%. Nov-15-23 11:04AM BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks ... BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of …Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.BioCardia Reports First Quarter 2023 Business Highlights and Financial Results. BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications. BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023.

5 Sep 2023 ... Biocardia stock dropped from about $2 on July 21 to $1.10 on July 24, when the concerns of the DSMB were first revealed. After drifting down ...

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE …

Mr. McClung BCDA stock SEC Form 4 insiders trading. David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018.1,600 units of BCDA stock worth $4,096 on 5 November 2018.Find real-time BCDA - BioCardia Inc stock quotes, company profile, news and forecasts from CNN Business. Jul 24, 2023 · July 24, 2023. SUNNYVALE, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP ... Find the latest BioCardia, Inc. (6JU.F) stock quote, history, news and other vital information to help you with your stock trading and investing.The estimated Net Worth of Peter Altman is at least $851 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $173,371 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.Nov 15, 2023 · BioCardia (NASDAQ:BCDA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment?We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation. With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Find the latest BioCardia, Inc. (6JU.F) stock quote, history, news and other vital information to help you with your stock trading and investing.Analysts who follow BioCardia Inc on average expect it to increase 1150.00% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns BioCardia Inc an Analyst Ranking of 25, which means it ranks higher than 25 of stocks, based on data compiled by InvestorsObserver.Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. (GlobeNewswire) -15.27%. Nov-15-23 11:04AM. BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study.The BioCardia, Inc. stock price fell by -0.92% on the last day (Wednesday, 29th Nov 2023) from $0.686 to $0.680. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 11.30% from a day low at $0.639 to a day high of $0.711. The price has fallen in 8 of the last 10 days and is down by -36.45% for this period.

David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth 4,096$ on 5 November 2018.

Mr. Fernandez BCDA stock SEC Form 4 insiders trading. Fernando has made over 1 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 14,277 units of BCDA stock worth $10,292 on 13 January 2018.. The largest trade he's ever made was exercising 14,277 units of …BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today …Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000.Nov 15, 2023 · BioCardia, Inc. price | BioCardia, Inc. Quote Zacks Rank & Other Stocks to Consider. BioCardia currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the overall healthcare sector ... The estimated Net Worth of Richard M Krasno is at least $411 Thousand dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $140,700 and over the last 16 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.Nov 24, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for BioCardia stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for BCDA. The average twelve-month price prediction for BioCardia is $4.00 with a high price target of $4.00 and a low price target of $4.00. The BioCardia stock prediction for 2025 is currently $ 139.62, assuming that BioCardia shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 20,667.78% increase in the BCDA stock price.

Stock Price Forecast. The 1 analysts offering 12-month price forecasts for BioCardia Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate ...

Discover historical prices for ME stock on Yahoo Finance. View daily, weekly or monthly format back to when 23andMe Holding Co. stock was issued.

BioCardia Inc. Stock Earnings. The value each BCDA share was expected to gain vs. the value that each BCDA share actually gained. BioCardia Inc. ( BCDA) reported Q2 2023 earnings per share (EPS) of -$0.17, missing estimates of -$0.16 by 7.23%. In the same quarter last year, BioCardia Inc. 's earnings per share (EPS) was -$0.14.SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.BioCardia's stock was trading at $0.8269 at the start of the year. Since then, BCDAW stock has decreased by 86.7% and is now trading at $0.11. View the best growth stocks for 2023 here. This page (NASDAQ:BCDAW) was last updated on 10/17/2023 by MarketBeat.com Staff. Get 30 Days of MarketBeat All Access Free.BioCardia : FORM OF SECURITIES PURCHASE AGREEMENT - Form 8-K Nov. 16: PU BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules Nov. 16: AQ Dec 2, 2023 · Complete BioCardia Inc. stock information by Barron's. View real-time BCDA stock price and news, along with industry-best analysis. Nov 14, 2023 · BioCardia Inc (BCDA) stock is unmoved 0% while the S&P 500 is higher by 1.44% as of 4:00 PM on Monday, Nov 13. BCDA is unmoved $0.00 from the previous closing price of $0.40 on volume of 39,170,298 shares. Over the past year the S&P 500 has gained 13.09% while BCDA has fallen -78.61%. BCDA lost -$0.63 per share the over the last 12 months. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, under the caption titled ...

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq ... SAN CARLOS, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- BioCardia ®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today reported financial results for the first quarter of 2021 and filed its quarterly report on Form 10-Q for the three months …8 Nov 2023 ... Stock name: BCDA, Stock Code: BCDA, Company: BioCardia, Inc., Sector: Healthcare.Mr. McClung BCDA stock SEC Form 4 insiders trading. David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018.1,600 units of BCDA stock worth $4,096 on 5 November 2018.Instagram:https://instagram. pre market stock screenerdefender 90 carrolox stocksjim stock SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ... peter lynch bookhow to buy elon coin The estimated Net Worth of Peter Altman is at least $849 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $171,654 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia. start up engine If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Earnings for BioCardia are expected to decrease in the coming year, from ($0.54) to ($0.56) per share. BioCardia has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates. Read More.BioCardia (Nasdaq:BCDA) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech BioCardia NasdaqCM:BCDA …